Premium
KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH‐DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL
Author(s) -
Ferrero S.,
Rossi D.,
Bruscaggin A.,
Evangelista A.,
Di Rocco A.,
Spina V.,
Stefoni V.,
Ghione P.,
Barbero D.,
Monitillo L.,
Gomes Da Silva M.,
Santoro A.,
Molinari A.,
Ferreri A.,
Piccin A.,
Cortelazzo S.,
Ladetto M.,
Gaidano G.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_83
Subject(s) - mantle cell lymphoma , cdkn2a , kras , oncology , medicine , biology , cancer research , genetics , gene , lymphoma , mutation , cancer
84 KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH‐DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL S. Ferrero* | D. Rossi | A. Bruscaggin | A. Evangelista | A. Di Rocco | V. Spina | V. Stefoni | P. Ghione | D. Barbero | L. Monitillo | M. Gomes Da Silva | A. Santoro | A. Molinari | A. Ferreri | A. Piccin | S. Cortelazzo | M. Ladetto | G. Gaidano Molecular Biotechnologies and Health Sciences ‐ Hematology Division, Università di Torino, Torino, Italy; Hematology, Oncology, Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland; Hematology, Institute of Oncology Research, Bellinzona, Switzerland; Clinical Epidemiology, Città della Salute e della Scienza and CPO Piemonte, Torino, Italy; Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy; University of Bologna, Institute of Hematology "L. e A. Seràgnoli, Bologna, Italy; Department of Hematology, Instituto Português de Oncologia de Lisboa, Lisbona, Portugal; Humanitas Clinical and Research Center, Humanitas Cancer Center, Rozzano, Italy; Hematology, Ospedale degli Infermi, Rimini, Italy; Unit of Lymphoid Malignancies, Department of Onco‐Haematology, IRCCS San Raffaele Scientific Institute, Milan, Italy; Department of Hematology, Ospedale Generale, Bolzano, Italy; Gavazzeni, Clinica Humanitas, Bergamo, Italy; Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, SC Ematologia, Alessandria, Italy; Department of Translational Medicine, University of Eastern Piedmont, Division of Hematology, Novara, Italy